Transcat, Inc.
NASDAQ:TRNSIndustrial - Distribution
+$2.00 today
- Market cap
- $937.19M
- Beta
- 0.70
- P/E (TTM)
- 150.2
- EPS (TTM)
- $0.62
Volume 0.14M
Average 0.16M
Financial health
Transcat, Inc. financial health
Start with the overall verdict and the rule-based risk checks for TRNS, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
The balance sheet looks mixed, so liquidity and debt trends deserve a closer read.
Cash & Investments
$4.94M
Debt Cushion
-$123.94M
Current Ratio
0.0x
Interest Coverage
5.2x
Risk checks
6 of 10 flagged
Manageable net debt
3.1×
Passes when: Net debt is below 3× EBITDA
Debt repayable from cash flow
6.6 yrs
Passes when: Free cash flow could repay all debt within 5 years
Debt growth in line with sales
26.0% vs 12.9%
Passes when: 3-year debt growth is no more than 5 points above revenue growth
Tangible equity base
98.4%
Passes when: Goodwill and intangibles are below 50% of equity
Contained stock compensation
21.7%
Passes when: Stock-based compensation is below 20% of operating cash flow
Limited dilution
+4.3%/yr
Passes when: Diluted share count grows less than 2% a year
Positive equity
Positive
Passes when: Shareholders' equity is above zero
Interest covered
2.9×
Passes when: Operating income is at least 1.5× interest expense
Short-term liquidity
2.3×
Passes when: Current assets are at least 1× current liabilities
Stable Altman Z-Score
5.46 → 3.42
Passes when: Z-Score is not falling while below the 2.99 safe zone
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Average7 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Safe zone4.06
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$4.94M
Q4 2025
Quick Ratio
0.0x
Q3 2026
Current Ratio
0.0x
Q3 2026
Cash Ratio
0.0x
Q3 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$128.88M
Q4 2025
Debt/Equity
0.0x
Q3 2026
Debt/Assets
0.0x
Q3 2026
Interest Coverage
5.2x
Q3 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$0.00
Q4 2025
Assets
$480.49M
Q4 2025
Liabilities
$179.87M
Q4 2025
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q4 2025).
Competitor health
How does Transcat, Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Mettler-Toledo International Inc. MTD:NYSE | $34.59B | -99.14 | 0.63 | 1.83 | 16.32 | 0.81 | 1.14 | 0.06 |
Bio-Techne Corporation TECH:NASDAQ | $11.44B | 0.14 | 0.11 | 0.07 | 46.60 | 3.35 | 4.55 | 1.62 |
Bio-Rad Laboratories, Inc. BIO:NYSE | $9.85B | 0.21 | 0.14 | 0.83 | 5.52 | 4.19 | 5.62 | 1.03 |
UFP Technologies, Inc. UFPT:NASDAQ | $2.36B | 0.36 | 0.23 | 1.20 | 9.42 | 1.52 | 2.68 | 0.27 |
TIC Solutions, Inc. TIC:NYSE | $2.32B | 0.79 | 0.39 | 7.59 | 0.10 | 3.20 | 3.20 | 1.38 |
NeoGenomics, Inc. NEO:NASDAQ | $2.07B | 0.56 | 0.35 | Net cash | — | 3.94 | 4.26 | 1.81 |
BioLife Solutions, Inc. BLFS:NASDAQ | $1.89B | 0.05 | 0.04 | Net cash | — | 4.63 | 5.94 | 1.44 |
QuidelOrtho Corporation QDEL:NASDAQ | $736.90M | 1.48 | 0.49 | Net cash | — | 0.90 | 1.50 | 0.18 |
Alpha Teknova, Inc. TKNO:NASDAQ | $516.43M | 0.22 | 0.15 | Net cash | — | 3.64 | 4.58 | 0.78 |
Standard BioTools Inc. LAB:NASDAQ | $279.27M | 0.07 | 0.05 | 0.97 | — | 4.01 | 4.19 | 1.09 |
Questions
Financial health questions
Common questions about TRNS's balance sheet, answered from the reported figures.
Is TRNS's balance sheet healthy?
Transcat, Inc. (TRNS) has a current ratio of 0.00, a quick read on short-term liquidity.
How leveraged is TRNS?
Debt to equity is 0.00, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.